Advertisement

Short-term Therapy for Acute Myelogenous Leukaemia in Younger Patients

  • T. A. Lister
  • A. Z. S. Rohatiner
  • M. L. Slevin
  • H. S. Dhaliwal
  • R. Bell
  • G. Henry
  • H. Thomas
  • J. Amess
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 28)

Abstract

It has now been repeatedly demonstrated that it is possible to achieve complete remission (CR) in the majority of younger adults with acute myelogenous leukaemia (AML) [4, 5, 7, 11, 12], and that approximately one-fifth of patients in whom this is achieved will continue well without recurrence for many years [2, 6, 8, 10]. These observations have naturally stimulated considerable research in to how these achievements may be translated into cure being probable for the majority rather than possible for the minority. In general, the trend has been to increase the quantity of initial therapy to the limits of bone marrow tolerance, which has been considerably extended by the availability of platelet concentrates and powerful broad spectrum antibiotics. In 1978 such an approach was introduced at St. Bartholomew’s Hospital. In the light of there being no convincing evidence that maintenance therapy prolonged remission following very intensive initial treatment, and some (evidence) to the contrary [3, 9], it was decided to limit the duration of the programme to approximately 6 months by terminating all therapy after a maximum of six cycles of adriamycin (adria), cytosine arabinoside (araC) and 6-thioguanine (6-TG) given at approximately 3 weekly intervals.

Keywords

Complete Remission Acute Myelogenous Leukaemia Cytosine Arabinoside Blast Cell Count Remission Induction Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bell R, Rohatiner AZS, Slevin ML, Ford JM, Dhaliwal HS, Henry G, Birkhead BG, Amess JAL, Malpas JS, Lister TA (1982) Short-term therapy for acute myelogenous leukaemia. Br Med J 284: 1221–1229CrossRefGoogle Scholar
  2. 2.
    Coltman CA Jr, Freireich EJ, Savage RA, Gehan EA (1979) Long-term survival of adults with acute leukaemia. Proc Am Soc Clin Onc 21: 389Google Scholar
  3. 3.
    Embury SH, Elias L, Heller PH, Hood CE, Greenberg PL, Schrier SL (1977) Long-term survival in adults with acute myelocytic leukaemia. West J Med 126:267–272PubMedGoogle Scholar
  4. 4.
    Gale RP, Cline MJ (1977) High remission induction rate in acute myelogenous leukaemia. Lancet I: 497–499CrossRefGoogle Scholar
  5. 5.
    Glucksberg H, Cheever MA, Farewell VT, Fefer A, Sale GE (1981) High-dose combination chemotherapy for acute non-lymphoblastic leukaemia in adults. Cancer 48: 1073–1081PubMedCrossRefGoogle Scholar
  6. 6.
    Lister TA, Johnson SAN, Bell R, Henry G, Malpas JS (1981) Progress in acute myelogenous leukaemia. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukaemia 4. Springer, Berlin Heidelberg New York, p 38 (Haematology and Blood Transfusion, vol 26)Google Scholar
  7. 7.
    Mayer RJ, Coral FS, Rosenthal DS (to be published) Intensive post induction chemotherapy in the management of patients with acute myelogenous leukaemia. Cancer Treat RepGoogle Scholar
  8. 8.
    McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ (1981) Chemoimmunotherapy of adult acute leukaemia. Cancer 47: 1256–1261PubMedCrossRefGoogle Scholar
  9. 9.
    Peterson BA, Bloomfield CD (1977) Prolonged maintained remission of adult acute non-lymphocytic leukaemia. Lancet II: 158–160CrossRefGoogle Scholar
  10. 10.
    Peterson BA, Bloomfield CH (1981) Long-term disease-free survival in acute non-lymphocytic leukaemia. Blood 57, 6: 1144–1147PubMedGoogle Scholar
  11. 11.
    Preisler HD, Brecher M, Browman G, Early AP, Walker IR, Raza A, Freeman A (to be published) The treatment of acute myelocytic leukaemia in children and young adultsGoogle Scholar
  12. 12.
    Rees JKL, Sandler RM, Challener J, Hayhoe FGJ (1977) Treatment of acute myeloid leukaemia with a triple cytotoxic regimen (DAT). Br J Cancer 36:770–776PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • T. A. Lister
  • A. Z. S. Rohatiner
  • M. L. Slevin
  • H. S. Dhaliwal
  • R. Bell
  • G. Henry
  • H. Thomas
  • J. Amess

There are no affiliations available

Personalised recommendations